Bookmark and Share
BioAssay: AID 588804

Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds

Name: Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds. ..more
_
   
 Tested Compounds
 Tested Compounds
All(3)
 
 
Inactive(3)
 
 
 Tested Substances
 Tested Substances
All(3)
 
 
Inactive(3)
 
 
 Related BioAssays
 Related BioAssays
AID: 588804
Data Source: The Scripps Research Institute Molecular Screening Center (NEURO2A_CYTOX_INH_ABSORB_6XCC50)
BioAssay Type: Panel, Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
BioAssay Version:
Deposit Date: 2011-11-17
Hold-until Date: 2012-05-31
Modify Date: 2012-05-31

Data Table ( Complete ):           All
Tested Compounds:
Depositor Specified Assays
Show more
AIDNameTypeProbeComment
2130Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).screening Primary screen (PME-1 inhibitors)
2143Summary of probe development efforts to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).summary3 Summary (PME-1 inhibitors)
2174Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).screening Counterscreen (LYPLA1 inhibitors)
2171Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).screening Confirmation assay (PME-1 inhibitors)
2177Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).screening Counterscreen (LYPLA2 inhibitors)
2232Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of lysophospholipase 2 (LYPLA2).screening Counterscreen confirmation (LYPLA2 inhibitors)
2233Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of lysophospholipase 1 (LYPLA1).screening Counterscreen confirmation (LYPLA1 inhibitors)
2291Fluorescence polarization-based Maybridge primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).screening Primary screen (PME-1 inhibitors, Maybridge Library)
2363Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Inhibition of PME-1-mediated demethylation of PP2ascreening MOA assay (Demethylation of PP2a)
2365Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Luminescence-based counterscreen assay to identify cytotoxic compoundsconfirmatory Counterscreen (Cytotoxicity HEC 293T)
2366Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) IC50confirmatory ABPP dose response screen (PME-1 inhibitors)
2368Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) Gel Filtration Assayscreening MOA assay (PME-1 inhibitors, gel filtration assay)
2369Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) Inhibitionscreening ABPP screen (PME-1 inhibitors)
2371Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) IC50: Purified enzymeconfirmatory ABPP dose response screen (PME-1 inhibitors, purified enzyme)
463090Late stage assay provider results from the probe development effort to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1): LC-MS/MS assay to assess binding of compounds to active siteother1 MOA assay (PME-1 inhibitors, LC-MS assay)
463091Late stage assay provider results from the probe development effort to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1): luminescence-based biochemical dose response assay to determine cytotoxicity of inhibitor compoundsconfirmatory Counterscreen (Cytotoxicity HeLa)
463146Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Fluorescence-based biochemical gel-based ABPPother ABPP profiling (PME1 inhibitors in singlicate)
463149Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityother ABPP profiling (PME1 inhibition and selectivity in singlicate)
463131Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): fluorescence-based cell-based inhibitionscreening ABPP profiling (PME1 inhibitors in singlicate)
463130Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Gel-based Activity-Based Protein Profiling (ABPP) IC50 Set 1confirmatory ABPP profiling dose response (PME1 inhibitors in triplicate)
463124Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Gel-based Activity-Based Protein Profiling (ABPP) IC50 Set 2confirmatory ABPP profiling dose response (PME1 inhibitors in triplicate)
463132Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Inhibition of PME-1-mediated demethylation of PP2Ascreening MOA assay (PP2a demethylation)
588835Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based dose response cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) ABHD10 selectivity assayother
602468Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition and selectivity among cysteine-reactive proteinsother
602485Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10 in vivoother
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Benjamin Cravatt, TSRI
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 CA132630
Grant Proposal PI: Benjamin Cravatt, TSRI
External Assay ID: NEURO2A_CYTOX_INH_ABSORB_6XCC50

Name: Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds.

Description:

Protein phosphatase methylesterase-1 (PME-1)-mediated methylesterification is thought to control the binding of different subunits to protein phosphatase 2A (PP2A) (1), which, along with protein phosphatase 1 (PP1), is responsible for > 90% of all serine/threonine phosphatase activity (2). PME-1 has also been identified as a protector of sustained ERK pathway activity in malignant gliomas (3), suggesting a link between cancer progression and PME-1-regulated methylesterification. A fluorescence-polarization activity-based protein profiling (fluopol-ABPP) HTS assay for PME-1 inhibitor discovery (AIDs 2130 and 2171) unveiled a phenomenal class of potent and selective inhibitors, the aza-beta lactams (ABLs). During medicinal chemistry campaign to refine ABL inhibitors for PME-1 (See Probe Report for ML174 on the NCBI bookshelf http://www.ncbi.nlm.nih.gov/books/NBK47352/), we observed that one of the common anti-targets of several ABL members was the uncharacterized serine hydrolase abhydrolase domain containing protein 10 (ABHD10). We have preliminary evidence that ABHD10 functions as a lipase in situ (unpublished); however is physiological substrates and biological role(s) have not yet been explored. A principle goal of post-genomic research is to elucidate the molecular and cellular roles of uncharacterized enzymes like ABHD10, work that requires selective chemical tools to inactivate enzyme activity in a controlled manner.

References:

1. Wu, J., Tolstykh, T., Lee, J., Boyd, K., Stock, J. B., Broach, J. R. (2000). Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. Embo J. 19, 5672-5681.
2. Oliver, C. J., Shenolikar, S. (1998). Physiologic importance of protein phosphatase inhibitors. Front. Biosci. 3, D961-972.
3. Puustinen, P., Junttila, M. R., Vanhatupa, S., Sablina, A. A., Hector, M. E., Teittinen, K., Raheem, O., Ketola, K., Lin, S., Kast, J., Haapasalo, H., Hahn, W. C., Westermarck, J. (2009). PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 69, 2870-2877.

Keywords:

late stage, late stage AID, assay provider, powders, abhdyrolase domain containing protein 10, ABHD10, uncharacterized, PME-1, protein phosphatase methylesterase 1, PPME-1, counterscreen, cytotoxicity, Neuro-2A, CC50, dose response, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Panel Information
Assays
PID§NameSubstancePanel TargetsDescription
ActiveInactive
1Serum-free media3
2Serum containing media3

§ Panel component ID.
Protocol
Assay Overview:

The purpose of this assay is to determine cytotoxicity of powder samples of synthetic inhibitor compounds belonging to the aza-beta lactam scaffold. In this assay, Neuro-2A murine neuroblastoma cells in either serum-free media or media containing fetal calf serum (FCS) are incubated with test compounds, followed by determination of cell viability. The assay utilizes the WST-1 substrate that is converted into colorimetric formazan dye by the metabolic activity of viable cells. The amount of formed formazan directly correlates to the number of metabolically active cells in the culture. As designed, compounds that reduce cell viability will result in decreased absorbance of the dye.

Protocol Summary:

This assay was started by seeding Neuro-2A murine neuroblastoma cells in DMEM medium (100 uL; 15,000 cells/well) into a 96-well plate. After 36 hours, the medium was removed and inhibitors were added in both serum-free media and media supplemented with fetal calf serum (FCS) (final compound concentration 0-10 uM in 100 uL total volume, 1% DMSO). Cells were incubated for 48 hours at 37 C in a humidified incubator and cell viability was determined using the WST-1 assay according to manufacturer instructions. CC50 values for inhibition of ABHD10 were determined from dose-response curves from six replicates at each inhibitor concentration (7-point 1:5 dilution series from 10 uM to 0.00064 uM).

The % surviving cells for each well was calculated as follows:

%_Surviving_Cells = ( ABS_Test_Compound - Median_ABS_Low_Control ) / ( Median_ABS_High_Control - Median_ABS_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing cells in the presence of test compound.
High_Control is defined as wells containing cells treated with media only (no compound).
Low_Control is defined as wells containing no cells (media only).

In the event that the highest test concentration (10 uM) did not result in at least 50% cell death, the CC50 value is reported as being greater than the highest test concentration (10 uM). Otherwise, the CC50 value for each test compound was determined by plotting percent surviving cells against the log of the compound concentration. A three parameter equation describing a sigmoidal dose-response curve was then fitted using GraphPad Prism (GraphPad Software Inc), and the software-generated CC50 values are reported.

PubChem Activity Outcome and Score:

The following applies to each panel in this assay:

Compounds with CC50 less than or equal to 5 uM were considered active (cytotoxic). Compounds with CC50 greater than 5 uM were considered inactive (non-cytotoxic).

Activity score was then ranked by the potency of the compounds with fitted curves, with the most potent compounds assigned the highest activity scores.

Serum-free media score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.

Serum containing media score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.

Overall Activity Outcome and Score:

Compounds with CC50 less than or equal to 5 uM in either panel were considered active (cytotoxic). Compounds with CC50 greater than 5 uM in both panels were considered inactive (non-cytotoxic).

The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.

List of Reagents:

Neuro-2A murine cells (provided by Assay Provider)
DMEM Medium (CellGro 10-017-CV)
FCS (Omega Scientific, FB-01)
WST-1 reagent (Roche)
96-well plates (Corning)
Comment
This assay was performed by the assay provider with powder samples of synthetic compounds.
Categorized Comment
BAO: version: 1.4b1090

BAO: bioassay specification: assay stage: secondary: counter screening

BAO: bioassay specification: assay biosafety level: bsl1

BAO: bioassay specification: assay measurement type: endpoint assay

BAO: bioassay specification: assay readout content: assay readout method: regular screening

BAO: bioassay specification: assay readout content: content readout type: single readout

BAO: meta target detail: binding reporter specification: interaction: protein-small molecule

BAO: detection technology: spectrophotometry: absorbance

Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Outcome [Serum-free]One of Active, Inactive, or Not Tested1Outcome
2Score [Serum-free]BioAssay score.1Integer
3Qualifier [Serum-free]Qualifier identifies if the resultant CC50 was determined manually to be greater than its listed CC50.1String
4CC50 [Serum-free]*The value for the concentration at which 50% of surviving cells are observed in serum-free medium; CC50 shown in micromolar.1FloatμM
5Surviving Cells at 10 uM [1] [Serum-free] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-free medium; replicate [1]1Integer%
6Surviving Cells at 10 uM [2] [Serum-free] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-free medium; replicate [2]1Integer%
7Surviving Cells at 10 uM [3] [Serum-free] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-free medium; replicate [3]1Integer%
8Surviving Cells at 10 uM [4] [Serum-free] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-free medium; replicate [4]1Integer%
9Surviving Cells at 10 uM [5] [Serum-free] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-free medium; replicate [5]1Integer%
10Surviving Cells at 10 uM [6] [Serum-free] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-free medium; replicate [6]1Integer%
11Surviving Cells at 2 uM [1] [Serum-free] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-free medium; replicate [1]1Integer%
12Surviving Cells at 2 uM [2] [Serum-free] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-free medium; replicate [2]1Integer%
13Surviving Cells at 2 uM [3] [Serum-free] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-free medium; replicate [3]1Integer%
14Surviving Cells at 2 uM [4] [Serum-free] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-free medium; replicate [4]1Integer%
15Surviving Cells at 2 uM [5] [Serum-free] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-free medium; replicate [5]1Integer%
16Surviving Cells at 2 uM [6] [Serum-free] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-free medium; replicate [6]1Integer%
17Surviving Cells at 0.4 uM [1] [Serum-free] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-free medium; replicate [1]1Integer%
18Surviving Cells at 0.4 uM [2] [Serum-free] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-free medium; replicate [2]1Integer%
19Surviving Cells at 0.4 uM [3] [Serum-free] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-free medium; replicate [3]1Integer%
20Surviving Cells at 0.4 uM [4] [Serum-free] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-free medium; replicate [4]1Integer%
21Surviving Cells at 0.4 uM [5] [Serum-free] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-free medium; replicate [5]1Integer%
22Surviving Cells at 0.4 uM [6] [Serum-free] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-free medium; replicate [6]1Integer%
23Surviving Cells at 0.08 uM [1] [Serum-free] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-free medium; replicate [1]1Integer%
24Surviving Cells at 0.08 uM [2] [Serum-free] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-free medium; replicate [2]1Integer%
25Surviving Cells at 0.08 uM [3] [Serum-free] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-free medium; replicate [3]1Integer%
26Surviving Cells at 0.08 uM [4] [Serum-free] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-free medium; replicate [4]1Integer%
27Surviving Cells at 0.08 uM [5] [Serum-free] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-free medium; replicate [5]1Integer%
28Surviving Cells at 0.08 uM [6] [Serum-free] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-free medium; replicate [6]1Integer%
29Surviving Cells at 0.016 uM [1] [Serum-free] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-free medium; replicate [1]1Integer%
30Surviving Cells at 0.016 uM [2] [Serum-free] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-free medium; replicate [2]1Integer%
31Surviving Cells at 0.016 uM [3] [Serum-free] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-free medium; replicate [3]1Integer%
32Surviving Cells at 0.016 uM [4] [Serum-free] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-free medium; replicate [4]1Integer%
33Surviving Cells at 0.016 uM [5] [Serum-free] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-free medium; replicate [5]1Integer%
34Surviving Cells at 0.016 uM [6] [Serum-free] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-free medium; replicate [6]1Integer%
35Surviving Cells at 0.0032 uM [1] [Serum-free] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-free medium; replicate [1]1Integer%
36Surviving Cells at 0.0032 uM [2] [Serum-free] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-free medium; replicate [2]1Integer%
37Surviving Cells at 0.0032 uM [3] [Serum-free] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-free medium; replicate [3]1Integer%
38Surviving Cells at 0.0032 uM [4] [Serum-free] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-free medium; replicate [4]1Integer%
39Surviving Cells at 0.0032 uM [5] [Serum-free] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-free medium; replicate [5]1Integer%
40Surviving Cells at 0.0032 uM [6] [Serum-free] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-free medium; replicate [6]1Integer%
41Surviving Cells at 0.00064 uM [1] [Serum-free] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-free medium; replicate [1]1Integer%
42Surviving Cells at 0.00064 uM [2] [Serum-free] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-free medium; replicate [2]1Integer%
43Surviving Cells at 0.00064 uM [3] [Serum-free] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-free medium; replicate [3]1Integer%
44Surviving Cells at 0.00064 uM [4] [Serum-free] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-free medium; replicate [4]1Integer%
45Surviving Cells at 0.00064 uM [5] [Serum-free] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-free medium; replicate [5]1Integer%
46Surviving Cells at 0.00064 uM [6] [Serum-free] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-free medium; replicate [6]1Integer%
47Outcome [Serum]One of Active, Inactive, or Not Tested2Outcome
48Score [Serum]BioAssay score.2Integer
49Qualifier [Serum]Qualifier identifies if the resultant CC50 was determined manually to be greater than its listed CC50.2String
50CC50 [Serum]*The value for the concentration at which 50% of surviving cells are observed in serum-containing medium; CC50 shown in micromolar.2Float
51Surviving Cells at 10 uM [1] [Serum] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-containing medium; replicate [1]2Integer%
52Surviving Cells at 10 uM [2] [Serum] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-containing medium; replicate [2]2Integer%
53Surviving Cells at 10 uM [3] [Serum] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-containing medium; replicate [3]2Integer%
54Surviving Cells at 10 uM [4] [Serum] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-containing medium; replicate [4]2Integer%
55Surviving Cells at 10 uM [5] [Serum] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-containing medium; replicate [5]2Integer%
56Surviving Cells at 10 uM [6] [Serum] (10μM**)Value of percent surviving cells at 10 uM compound concentration in serum-containing medium; replicate [6]2Integer%
57Surviving Cells at 2 uM [1] [Serum] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-containing medium; replicate [1]2Integer%
58Surviving Cells at 2 uM [2] [Serum] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-containing medium; replicate [2]2Integer%
59Surviving Cells at 2 uM [3] [Serum] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-containing medium; replicate [3]2Integer%
60Surviving Cells at 2 uM [4] [Serum] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-containing medium; replicate [4]2Integer%
61Surviving Cells at 2 uM [5] [Serum] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-containing medium; replicate [5]2Integer%
62Surviving Cells at 2 uM [6] [Serum] (2μM**)Value of percent surviving cells at 2 uM compound concentration in serum-containing medium; replicate [6]2Integer%
63Surviving Cells at 0.4 uM [1] [Serum] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-containing medium; replicate [1]2Integer%
64Surviving Cells at 0.4 uM [2] [Serum] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-containing medium; replicate [2]2Integer%
65Surviving Cells at 0.4 uM [3] [Serum] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-containing medium; replicate [3]2Integer%
66Surviving Cells at 0.4 uM [4] [Serum] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-containing medium; replicate [4]2Integer%
67Surviving Cells at 0.4 uM [5] [Serum] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-containing medium; replicate [5]2Integer%
68Surviving Cells at 0.4 uM [6] [Serum] (0.4μM**)Value of percent surviving cells at 0.4 uM compound concentration in serum-containing medium; replicate [6]2Integer%
69Surviving Cells at 0.08 uM [1] [Serum] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-containing medium; replicate [1]2Integer%
70Surviving Cells at 0.08 uM [2] [Serum] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-containing medium; replicate [2]2Integer%
71Surviving Cells at 0.08 uM [3] [Serum] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-containing medium; replicate [3]2Integer%
72Surviving Cells at 0.08 uM [4] [Serum] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-containing medium; replicate [4]2Integer%
73Surviving Cells at 0.08 uM [5] [Serum] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-containing medium; replicate [5]2Integer%
74Surviving Cells at 0.08 uM [6] [Serum] (0.08μM**)Value of percent surviving cells at 0.08 uM compound concentration in serum-containing medium; replicate [6]2Integer%
75Surviving Cells at 0.016 uM [1] [Serum] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-containing medium; replicate [1]2Integer%
76Surviving Cells at 0.016 uM [2] [Serum] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-containing medium; replicate [2]2Integer%
77Surviving Cells at 0.016 uM [3] [Serum] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-containing medium; replicate [3]2Integer%
78Surviving Cells at 0.016 uM [4] [Serum] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-containing medium; replicate [4]2Integer%
79Surviving Cells at 0.016 uM [5] [Serum] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-containing medium; replicate [5]2Integer%
80Surviving Cells at 0.016 uM [6] [Serum] (0.016μM**)Value of percent surviving cells at 0.016 uM compound concentration in serum-containing medium; replicate [6]2Integer%
81Surviving Cells at 0.0032 uM [1] [Serum] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-containing medium; replicate [1]2Integer%
82Surviving Cells at 0.0032 uM [2] [Serum] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-containing medium; replicate [2]2Integer%
83Surviving Cells at 0.0032 uM [3] [Serum] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-containing medium; replicate [3]2Integer%
84Surviving Cells at 0.0032 uM [4] [Serum] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-containing medium; replicate [4]2Integer%
85Surviving Cells at 0.0032 uM [5] [Serum] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-containing medium; replicate [5]2Integer%
86Surviving Cells at 0.0032 uM [6] [Serum] (0.0032μM**)Value of percent surviving cells at 0.0032 uM compound concentration in serum-containing medium; replicate [6]2Integer%
87Surviving Cells at 0.00064 uM [1] [Serum] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-containing medium; replicate [1]2Integer%
88Surviving Cells at 0.00064 uM [2] [Serum] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-containing medium; replicate [2]2Integer%
89Surviving Cells at 0.00064 uM [3] [Serum] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-containing medium; replicate [3]2Integer%
90Surviving Cells at 0.00064 uM [4] [Serum] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-containing medium; replicate [4]2Integer%
91Surviving Cells at 0.00064 uM [5] [Serum] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-containing medium; replicate [5]2Integer%
92Surviving Cells at 0.00064 uM [6] [Serum] (0.00064μM**)Value of percent surviving cells at 0.00064 uM compound concentration in serum-containing medium; replicate [6]2Integer%

* Activity Concentration. ** Test Concentration. § Panel component ID.
Additional Information
Grant Number: 1 R01 CA132630

PageFrom: